Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | STS | P08842 | 10/20 | 0.73 |
| ▸ | CA1 | P00915 | 3/20 | 0.72 |
| ▸ | CA2 | P00918 | 3/20 | 0.72 |
| ▸ | CA9 | Q16790 | 3/20 | 0.72 |
| ▸ | ESR1 | P03372 | 2/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.72 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA6 | P23280 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11671118 | 1.00 | HSD17B1 (0.78) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11672003 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10134113 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14044784 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6691697 | 0.91 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| Ethylene SCHEMBL11572556 | 0.91 | KDM4E (0.66) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6694124 | 0.91 | KDM4E (0.71) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14416886 | 0.90 | HSD17B1 (0.76) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL13977649 | 0.90 | HSD17B1 (0.76) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL15868588 | 0.90 | HSD17B1 (0.76) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116725008-A | Synergistic nano microemulsion of mouse sterilant and application thereof | 广东省农业科学院植物保护研究所 | 2023-09-12 | — | — | CN | disclosed |
| CN-114041472-B | Device for adding improved nano sterilant | 内蒙古农业大学 | 2023-06-30 | — | — | CN | disclosed |
| US-8124596-B2 | Demethylpenclomedine analogs and their use as anti-cancer agents | DEKK-TEC, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090197844-A1 | Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents | DEKK-TEC, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-3963766-A | Process for separation of 19-nor-Δ4 -androstene-3,17-dione | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | HSD17B1 19/4885LMNA 3831/4885MAPT 4065/4885 |
| US-20090197844-A1 | Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents | MCL1, DNMT1, MYC | HSD17B1 2345/4885LMNA 1636/4885MAPT 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.